NASDAQ:PRTK

Paratek Pharmaceuticals (PRTK) Stock Forecast, Price & News

$2.23

+0.04 (+1.83%)

(As of 09/21/2023)

Compare

Today's Range: $2.19
▼
$2.24
50-Day Range: $2.17
▼
$2.23
52-Week Range: $1.29
▼
$3.65

Volume: 4.76 million shs
Average Volume: 724,253 shs
Market Capitalization: $127.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.58

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 60.3% Upside
$3.58 Price Target
Short Interest: Healthy
6.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.98
Upright™ Environmental Score
News Sentiment: 0.85
Based on 3 Articles This Week
Insider Trading: Selling Shares
$313,161 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

793rd out of 971 stocks

Biotechnology Industry

16th out of 25 stocks

3.0

Analyst's Opinion

Consensus Rating
Paratek Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.58, Paratek Pharmaceuticals has a forecasted upside of 60.3% from its current price of $2.23.
Amount of Analyst Coverage
Paratek Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.11% of the float of Paratek Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Paratek Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Paratek Pharmaceuticals has recently decreased by 6.71%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Paratek Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Paratek Pharmaceuticals does not have a long track record of dividend growth.

1.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Paratek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.
Environmental Sustainability
The Environmental Impact score for Paratek Pharmaceuticals is -2.98.

3.3

News and Social Media Coverage

News Sentiment
Paratek Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Paratek Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for PRTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paratek Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $313,161.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.
Percentage Held by Institutions
53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

PRTK Price History

30 days | 90 days | 365 days | Advanced Chart

PRTK Stock News Headlines

September 26, 2023 | americanbankingnews.com

Paratek Pharmaceuticals (NASDAQ:PRTK) Now Covered by Analysts at StockNews.com

September 26, 2023 | americanbankingnews.com

Paratek Pharmaceuticals (NASDAQ:PRTK) Share Price Crosses Above 200-Day Moving Average of $2.10

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 21, 2023 | finance.yahoo.com

Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals

September 21, 2023 | finance.yahoo.com

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

September 19, 2023 | finance.yahoo.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company

September 18, 2023 | bizjournals.com

Paratek Pharmaceuticals shareholders approve $462M buyout deal

September 18, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

October 1, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 12, 2023 | finance.yahoo.com

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

September 7, 2023 | finance.yahoo.com

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

August 10, 2023 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRTN, AMED, PRTK

August 7, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on Paratek Pharmaceuticals (PRTK)

August 4, 2023 | finance.yahoo.com

News Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Forecasts

August 3, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

August 3, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

July 27, 2023 | seekingalpha.com

PRTK Paratek Pharmaceuticals, Inc.

July 11, 2023 | finance.yahoo.com

NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital

July 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Paratek Pharmaceuticals (PRTK) Neutral Recommendation

July 10, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Paratek Pharmaceuticals (PRTK)

July 10, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

July 6, 2023 | msn.com

Paratek Pharmaceuticals (PRTK) Price Target Decreased by 41.87% to 3.16

June 27, 2023 | msn.com

Paratek antibiotic Nuzyra to receive EU orphan drug status

June 27, 2023 | msn.com

Paratek investor NexPoint warns it may vote against takeover deal

June 27, 2023 | finance.yahoo.com

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

June 27, 2023 | finance.yahoo.com

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital

June 27, 2023 | finance.yahoo.com

European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

See More Headlines

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:PRTK
Previous Symbol: NASDAQ:TSPT
CUSIP: 89354M10
CIK: 1178711
Web: www.paratekpharma.com
Phone: (617) 807-6600
Fax: 617-275-0039
Employees: 268
Year Founded: 1996

Price Target and Rating

Average Stock Price Forecast: $3.58
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.15
Forecasted Upside/Downside: +60.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,570,000.00
Net Margins: -35.44%
Pretax Margin: -35.35%
Return on Equity: N/A
Return on Assets: -40.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.52
Quick Ratio: 0.46

Sales & Book Value

Annual Sales: $160.27 million
Price / Sales: 0.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.08) per share
Price / Book: -0.72

Miscellaneous

Outstanding Shares: 57,320,000
Free Float: 52,736,000
Market Cap: $127.82 million
Optionable: Optionable
Beta: 1.70

Social Links

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Michael F. Bigham CPA (Age 65)
CPA, M.B.A., MBA, Exec. Chairman
Comp: $954.39k

Dr. Evan Loh FACC (Age 64)
FAHA, M.D., CEO & Director
Comp: $1.14M

Mr. Adam Woodrow (Age 56)
Pres & Chief Commercial Officer
Comp: $763.51k

Ms. Sarah Higgins (Age 48)
VP of Fin., Controller & Principal Accounting Officer

Mr. William M. Haskel (Age 61)
Sr. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.

Mr. Jonathan Light
Deputy Gen. Counsel & Chief Compliance Officer

Ms. Karen McGrath
Chief People Officer

Mr. Randall B. Brenner (Age 50)
Chief Devel. & Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRTK Stock - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares.
View PRTK analyst ratings or view top-rated stocks.
What is Paratek Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $2.15 to $5.00. On average, they predict the company's stock price to reach $3.58 in the next twelve months. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.
How have PRTK shares performed in 2023?: Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of 2023. Since then, PRTK shares have increased by 19.3% and is now trading at $2.23.
View the best growth stocks for 2023 here.
When is Paratek Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRTK earnings forecast.
How were Paratek Pharmaceuticals' earnings last quarter?: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings data on Thursday, August, 3rd. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. The specialty pharmaceutical company earned $39.99 million during the quarter, compared to the consensus estimate of $34.63 million.
What ETF holds Paratek Pharmaceuticals' stock ?: AltShares Event-Driven ET holds 17,764 shares of PRTK stock, representing 1.36% of its portfolio.

What other stocks do shareholders of Paratek Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).
What is Paratek Pharmaceuticals' stock symbol?: Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How do I buy shares of Paratek Pharmaceuticals?: Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Paratek Pharmaceuticals' stock price today?: One share of PRTK stock can currently be purchased for approximately $2.23.
How much money does Paratek Pharmaceuticals make?: Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $127.82 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis.
How many employees does Paratek Pharmaceuticals have?: The company employs 268 workers across the globe.
How can I contact Paratek Pharmaceuticals?: Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Paratek Pharmaceuticals (PRTK) Stock Forecast, Price & News

Paratek Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

PRTK Price History

PRTK Stock News Headlines

PRTK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PRTK Stock - Frequently Asked Questions

Overall MarketRank^™